{"nctId":"NCT00781937","briefTitle":"Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance","startDateStruct":{"date":"2008-10-30","type":"ACTUAL"},"conditions":["Metabolism and Nutrition Disorder","Obesity"],"count":422,"armGroups":[{"label":"Lira 3.0 mg","type":"EXPERIMENTAL","interventionNames":["Drug: liraglutide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"liraglutide","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Body Mass Index (BMI) of either 30 kg/m\\^2 or more or BMI of less than 30 kg/m\\^2 to 27 kg/m\\^2 with presence of co-morbidities\n* Stable body weight during the previous 3 months (less than 5 kg self-reported weight change)\n* Previously undergone dietary weight loss and was not able to maintain reduced weight\n\nExclusion Criteria:\n\n* Diagnosis of type 1 or type 2 diabetes\n* Previous treatment with GLP-1 (glucagon-like peptide-1) receptor agonists (including liraglutide or exenatide), within the last 3 months\n* Visit 1 thryoid stimulating hormone (TSH) outside of the range of 0.4-6.0 mIU/L\n* History of chronic pancreatitis or idiopathic acute pancreatitis\n* Obesity induced by other endocrinologic disorders (e.g., Cushing Syndrome)\n* Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial\n* Current participation in an organized diet reduction program (or within the last 3 months)\n* Currently using or have used within three months before this trial: pramlintide, sibutramine, orlistat, zonisamide, topiramate, phenteremine, or metformin\n* Previous surgical treatment for obesity (excluding liposuction if performed more than one year before trial entry)\n* History of major depressive disorder or a PHQ-9 (Patient Health Questionnaire-9) score of more than 15 within the last 2 years or history of other severe psychiatric disorders or diagnosis of an eating disorder\n* Subjects with a lifetime history of a suicide attempt or history of any suicidal behavior within the past month before entry into the trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Percentage Change in Fasting Body Weight From Baseline","description":"Subjects were weighed having fasted (consumed only water) since midnight the night before the visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.11","spread":"0.66"},{"groupId":"OG001","value":"-0.05","spread":"0.63"}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects Who Maintained Their run-in Fasting Weight Loss From Week 0","description":"Subjects who had a weight regain less than or equal to 0.5% of weight from Week 0 were regarded as maintenance of run-in fasting weight loss. Subjects were weighed having fasted (consumed only water) since midnight the night before the visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","spread":null},{"groupId":"OG001","value":"47.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects Who Lost More Than or Equal to 5% of Fasting Body Weight From Week 0","description":"Subjects were weighed having fasted (consumed only water) since midnight the night before the visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.5","spread":null},{"groupId":"OG001","value":"21.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Lost More Than 10% of Fasting Body Weight From Week 0","description":"Subjects were weighed having fasted (consumed only water) since midnight the night before the visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Weight Regain (Fasting) More Than or Equal to 5% From Week 0","description":"Subjects were weighed having fasted (consumed only water) since midnight the night before the visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"17.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Weight Regain (Fasting) More Than or Equal to 10% From Week 0","description":"Subjects were weighed having fasted (consumed only water) since midnight the night before the visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Greater Than 50% of Fasting run-in Weight Loss Maintained From Week 0","description":"Subjects were weighed having fasted (consumed only water) since midnight the night before the visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null},{"groupId":"OG001","value":"70.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Greater Than 75% of Fasting run-in Weight Loss Maintained From Week 0","description":"Subjects were weighed having fasted (consumed only water) since midnight the night before the visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.4","spread":null},{"groupId":"OG001","value":"54.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Weight","description":"Subjects were weighed having fasted (consumed only water) since midnight the night before the visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.7","spread":"0.66"},{"groupId":"OG001","value":"0.16","spread":"0.63"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Weight for Subjects Completing the Main Trial Period and Entering the Follow-up Period","description":"Subjects were weighed having fasted (consumed only water) since midnight the night before the visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.83","spread":"0.82"},{"groupId":"OG001","value":"0.41","spread":"0.78"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Pressure","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.31","spread":"0.90"},{"groupId":"OG001","value":"4.03","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.81","spread":"0.64"},{"groupId":"OG001","value":"2.15","spread":"0.61"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pulse","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.12","spread":"0.68"},{"groupId":"OG001","value":"3.15","spread":"0.65"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Lipid Profile: Triglycerides","description":"Subjects were tested having fasted (consumed only water) since midnight the night before the visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.04"},{"groupId":"OG001","value":"0.12","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Lipid Profile: Low Density Lipoprotein (LDL) Cholesterol","description":"Subjects were tested having fasted (consumed only water) since midnight the night before the visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.05"},{"groupId":"OG001","value":"0.33","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Lipid Profile: Total Cholesterol","description":"Subjects were tested having fasted (consumed only water) since midnight the night before the visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"0.06"},{"groupId":"OG001","value":"0.33","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Cardiovascular Biomarker: High Sensitivity C-reactive Protein (hsCRP)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.31","spread":"4.62"},{"groupId":"OG001","value":"1.70","spread":"4.51"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Meeting Metabolic Syndrome Criteria: ATP (Adult Treatment Panel) III at Week 56","description":"Metabolic syndrome status required at least 3 of 5 criteria met: Waist circumference (men ≥102cm, women ≥88cm); Triglycerides \\>1.7mmol/L; High density lipoprotein cholesterol (men \\<0.9mmol/L, women \\<1.1mmol/L) or on drug therapy; Blood pressure ≥130mmHg systolic or ≥85mmHg diastolic or on drug therapy; Fasting glucose ≥5.5mmol/L or on drug therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","spread":null},{"groupId":"OG001","value":"36.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Waist Circumference","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.36","spread":"0.62"},{"groupId":"OG001","value":"-0.86","spread":"0.59"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Mass Index (BMI)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.90","spread":"0.22"},{"groupId":"OG001","value":"0.15","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycaemic Control Parameter: HOMA-B (Homeostasis Model Assessment - Beta Cell Function)","description":"Change in beta-cell function percent values from Week 0 (X%) to Week 56 (Y%) was calculated \\[X% - Y%\\]. Beta-cell function was derived from fasting plasma glucose readings in blood samples using the HOMA method, which is based on the assumption that normal-weight subjects without diabetes aged \\<35 years have median beta-cell function indexed at 100%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.51","spread":"2.33"},{"groupId":"OG001","value":"6.16","spread":"2.27"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycaemic Control Parameter: HOMA-IR (Homeostasis Model Assessment - Insulin Resistance)","description":"Change in insulin resistance values from Week 0 (X) to Week 56 (Y) was calculated \\[X - Y\\]. Insulin resistance was derived from fasting serum insulin levels in blood samples using the HOMA method, which is based on the assumption that normal-weight subjects without diabetes aged \\<35 years have median insulin resistance indexed at 1.00.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.03"},{"groupId":"OG001","value":"0.08","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycaemic Control Parameter: Fasting Plasma Glucose (FPG)","description":"Subjects were tested having fasted (consumed only water) since midnight the night before the visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":"0.05"},{"groupId":"OG001","value":"-0.14","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycaemic Control Parameter: Fasting Serum Insulin","description":"Subjects were tested having fasted (consumed only water) since midnight the night before the visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.67"},{"groupId":"OG001","value":"2.35","spread":"0.65"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycaemic Control Parameter: HbA1c (Glycosylated Haemoglobin)","description":"Change in HbA1c percent values from Week 0 (X%) to Week 56 (Y%) was calculated \\[X% - Y%\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.03"},{"groupId":"OG001","value":"0.13","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Using Concomitant Medications (Antihypertensive Medications, Lipid Lowering Medications, or Antipsychotic Medications)","description":"Number of subjects using concomitant medications at Week 0 and Week 56, respectively","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Binge Eating Scale Scores by Week and Severity","description":"Binge Eating Scale (BES) scores are based on responses to the Binge Eating Scale Questionnaire, a 16-item self-reporting diagnostic tool scaled 0-46 (Non-binging: 0-17; Moderate: 17-26; Severe: 27-46)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"5.6"},{"groupId":"OG001","value":"7.8","spread":"6.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"5.6"},{"groupId":"OG001","value":"8.6","spread":"7.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"5.8"},{"groupId":"OG001","value":"6.9","spread":"6.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":212},"commonTop":["Nausea","Nasopharyngitis","Constipation","Diarrhoea","Headache"]}}}